Showing results (11-20 of 94) with videos related to
Sort By:
Pageof 10
Talanta|October 31, 2008
A new antibody immobilization strategy based on electrodeposition of nanometer-sized hydroxyapatite for label-free capacitive immunosensorLiu Yang, Wanzhi Wei, Xiaohua Gao, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|June 30, 2022
Efficacy and toxicity of the DPCPX nanoconjugate drug study for the treatment of spinal cord injury in ratsXiaohua Gao, Md Musfizur Hassan, Samiran Ghosh, et al.Oncology Reports|May 23, 2015
Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cellsDorrah Deeb, Xiaohua Gao, Yongbo Liu, et al.International Journal of Oncology|March 8, 2014
Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2Dorrah Deeb, Xiaohua Gao, Yong Bo Liu, et al.Journal of Experimental Therapeutics & Oncology|August 12, 2015
Role of telomerase in anticancer activity of pristimerin in prostate cancer cellsYong Bo Liu, Xiaohua Gao, Dorrah Deeb, et al.Molecules (Basel, Switzerland)|March 23, 2013
Telomerase reverse transcriptase (TERT) is a therapeutic target of oleanane triterpenoid CDDO-Me in prostate cancerYongbo Liu, Xiaohua Gao, Dorrah Deeb, et al.Journal of Experimental Therapeutics & Oncology|December 17, 2014
Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signalingXiaohua Gao, Yongbo Liu, Dorrah Deeb, et al.The Prostate|February 4, 2009
Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTORDorrah Deeb, Xiaohua Gao, Hao Jiang, et al.Journal of Carcinogenesis & Mutagenesis|May 31, 2014
Pristimerin Induces Apoptosis in Prostate Cancer Cells by Down-regulating Bcl-2 through ROS-dependent Ubiquitin-proteasomal Degradation PathwayYong Bo Liu, Xiaohua Gao, Dorrah Deeb, et al.Journal of Experimental Therapeutics & Oncology|May 5, 2017
Anticancer agent pristimerin inhibits IL-2 induced activation of T lymphocytesYongbo Liu, Xiaohua Gao, Dorrah Deeb, et al.Pageof 10